Skip to Main Content

Advertisement intended for health care professionals

American Society of Hematology Logo Open Menu
Cart
header search
Search
Skip Nav Destination

On Location

Updates from major medical meetings in the field of hematology/oncology
Rusfertide Shows Durable Responses in Phase III Study of Polycythemia Vera Free
Katie Robinson
November 24, 2025
Sapablursen Meets Primary Endpoint for Treatment of Polycythemia Vera Free
Lara C. Pullen, PhD
November 24, 2025
Bomedemstat Effectively Reduced Hematocrit in Phase II Trial of Patients With Previously Treated PV Free
Anna Azvolinsky, PhD
November 24, 2025
Anti-BCMA Anito-Cel CAR-T Offers More Efficient, Stable Therapy Free
Thomas R. Collins
November 24, 2025
Real-World Study of Cesni-Cel in Spain Demonstrates Efficacy on Par With Clinical Trial Results Free
Anna Azvolinsky, PhD
November 24, 2025
Rapid CAR-T Expansion Linked to Delayed Neurotoxicity After Cilta-Cel Infusion in Multiple Myeloma Free
Pinky Sharma
November 24, 2025
CDK4/6 Inhibition May Prevent Chemotherapy-Driven Expansion of TP53-Mutant Clonal Hematopoiesis Free
Katie Robinson
November 24, 2025
Early Data Show Mutant CALR-Specific Monoclonal Antibody Well Tolerated in Myelofibrosis Free
Katie Robinson
November 24, 2025
Lower MM Disease Burden Linked With Improved PFS, Safety After BCMA-Targeting CAR-T Free
Leah Lawrence
November 24, 2025
Nurse-Led Multidisciplinary Pathway Developed to Optimize Patient Journey in Acquired Hemophilia A Free
Katie Robinson
July 31, 2025
CHIP Drives Increased Mortality Unaltered by CAD Interventions Free
Khylia Marshall
July 31, 2025
Use of ACR/EULAR 2023 Criteria Results in Lower APS Diagnosis Rate Compared With Sydney Criteria Free
Leah Lawrence
July 31, 2025
Prophylactic Anticoagulation Reduces Death, VTE in Patients With Cancer Free
Khylia Marshall
July 31, 2025
Marstacimab Shows Long-Term Efficacy in Severe Hemophilia A, B Without Inhibitors Free
Katie Robinson
July 31, 2025
Concizumab Reduced Annualized Bleeding Rates in Hemophilia A, B Regardless of Target Joints Free
Katie Robinson
July 31, 2025
Caplacizumab Combo a ‘Historic’ New Option for Non-Severe iTTP Free
Leah Lawrence
July 31, 2025
Use of GLP-1 Agonists in Diabetic Patients With PV, ET Reduces VTE, Mortality Free
Lara C. Pullen, PhD
July 31, 2025
Half of Patients in EINSTEIN Jr. Trial Continue to Extended Anticoagulation Treatment Free
Lara C. Pullen, PhD
July 31, 2025
Daratumumab Shows Efficacy, Safety in Phase II Study of Previously Treated ITP Free
Katie Robinson
July 31, 2025
Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib Free
Anna Azvolinsky, PhD
July 17, 2025

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
Mid-November 2025

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2025 by American Society of Hematology
 
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals